Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
Florian Lordick(Leipzig University), Markus Moehler(Johannes Gutenberg University Mainz), Vladimir Moiseyenko(Institute of Oncology NN Petrov), Joon Oh Park(Samsung Medical Center), Akira Sawaki(Aichi Cancer Center), Helena Melezínková(Merck (Germany)), Sang Cheul Oh(Korea University), Constantin Volovăț(Institutul Regional de Oncologie), Heiko Götte(Merck (Germany)), Hyun Cheol Chung(Yonsei University), В. А. Горбунова(Taipei Veterans General Hospital), Ilhan Celik(Merck (Germany)), Pamela Salman(Fundación Arturo López Pérez), Yoon‐Koo Kang(Ulsan College), G. Kurteva(University Specialized Hospital for Active Treatment of Endocrinology), G. Bodoky(Unified Szent István and Szent László Hospital)
Cited by 838
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k